$AYTU News
Last published 1d ago
- 1d agoAYTUAytu BioPharma to Report Fiscal 2027 First Quarter Operational and Financial Results on November 16, 2026ACCESS NewswireAytu BioPharma, Inc. (the "Company" or "Aytu") (Nasdaq:AYTU), a pharmaceutical company focused on advancing innovative medicines for complex central nervous system diseases to improve the quality of life for patients, will report its operational and financial results for its fiscal 2027 first quarter after the market close on Monday, November 16, 2026. The Company has scheduled a conference call a ...
- 1mo agoAYTUAYTU BIOPHARMA (NASDAQ: AYTU) COMPANY PRESENTATION | LYTHAM PARTNERS FALL 2026 INVESTOR CONFERENCE - AYTU BIOPHARMA INCEarnings Call TranscriptsAll right. Hello, everyone, and thank you all for joining us during the Litham Partners Fall 2026 Investor Conference. Again, my name is Robert Bloom, Managing Partner here at Litham Partners. And up next, Josh Disbrough
- 1mo agoAYTUAytu BioPharma Fiscal 2026 Full Year and Q4 Earnings Call - AYTU BIOPHARMA INCEarnings Call TranscriptsGreetings. Welcome to the A2 Biopharma Fiscal 2026 Full Year and Q4 Earnings Call. At this time, all participants are in a listen-only mode. A question and answer session will follow the formal presentation. If anyone sh
- 1mo agoAYTUAytu BioPharma Reports Fiscal 2026 Full Year and Fourth Quarter Operational and Financial ResultsACCESS NewswireFourth quarter fiscal 2026 net revenue increased 6.4% to $16.1 million from $15.1 million in the prior-year quarterFourth quarter fiscal 2026 Adjusted EBITDA of $0.5 millionEXXUA net revenue of $6.6 million in fiscal
- 1mo agoAYTUAytu BioPharma to Report Fiscal 2026 Full Year and Fourth Quarter Operational and Financial Results on September 22, 2026ACCESS NewswireDENVER, CO / ACCESS Newswire / September 16, 2026 / Aytu BioPharma, Inc. , a pharmaceutical company focused on advancing innovative medicines for complex central
- 5mo agoAYTUAytu BioPharma to Present at the Planet MicroCap Las Vegas 2026 Investor Conference on June 17, 2026ACCESS NewswireDENVER, CO / ACCESS Newswire / June 1, 2026 / Aytu BioPharma, Inc. , a pharmaceutical company focused on advancing innovative medicines for complex central nervous system diseases
- 5mo agoAYTUAytu BioPharma to Participate in the Lytham Partners Spring 2026 Investor Conference on May 28, 2026ACCESS NewswireDENVER, CO / ACCESS Newswire / May 18, 2026 / Aytu BioPharma, Inc. , a pharmaceutical company focused on advancing innovative medicines for complex central nervous system diseases
- 6mo agoAYTUAytu BioPharma Reports Fiscal 2026 Third Quarter Operational and Financial ResultsACCESS NewswireEXXUA -- with only a partial quarter of full sales force support -- contributed $2.4 million in net revenue supported by rapid monthly compounding script growth ratesTotal net revenue of $12.4 millionAdjusted EBITDA1 of
- 6mo agoAYTUAytu BioPharma to Report Fiscal 2026 Third Quarter Operational and Financial Results on May 13, 2026ACCESS NewswireDENVER, CO / ACCESS Newswire / May 6, 2026 / Aytu BioPharma, Inc. , a pharmaceutical company focused on advancing innovative medicines for complex central nervous system diseases to
- 8mo agoAYTUApproval of Karbinal Er, Nda #022556 (Labeling)FDA Approved DrugsApproval Date: 03/10/2026; Drug Name: Karbinal Er, Nda #022556; Active Ingredients: CARBINOXAMINE MALEATE; Company: Aytu; Submission Status: Approval; Submission Classification: Labeling; Application Number: 022556
- 9mo agoAYTUAytu BioPharma Fiscal 2026 Q2 Earnings Call - AYTU BIOPHARMA INCEarnings Call TranscriptsGood day, everyone, and welcome to the A2 Biopharma Fiscal 2026 Second Quarter Earnings Call. At this time, all participants are placed on a listen-only mode, and we will open the floor for your questions and comments af
- 9mo agoAYTUAytu BioPharma Reports Fiscal 2026 Second Quarter Operational and Financial ResultsACCESS NewswireTotal net revenue of $15.2 millionAdjusted EBITDA1 of $ million, which includes EXXUA launch investments$30.0 million cash balance at December 31, 2025Company launched EXXUA™ extended-release
- 9mo agoAYTUAytu BioPharma Recaps Investor Day Held on January 20, 2026ACCESS NewswireDENVER, CO / ACCESS Newswire / January 20, 2026 / Aytu BioPharma, Inc. , a pharmaceutical company focused on advancing innovative medicines for complex central nervous system
- 9mo agoAYTUAytu BioPharma Highlights Opportunity for EXXUATM (gepirone) as New Way to Treat Major Depressive Disorder That Avoids Common Side Effects of Sexual Dysfunction and Significant Weight Gain following launch of EXXUAACCESS NewswireEXXUA addresses frequent causes of treatment discontinuation with first-line SSRIs and SNRIsNow commercially available through retail pharmacies and participating Aytu RxConnect® pharmacies to support patient
- 10mo agoAYTUAytu BioPharma to Participate in the Lytham Partners 2026 Investor Healthcare Summit on January 15, 2026ACCESS NewswireDENVER, CO / ACCESS Newswire / January 13, 2026 / Aytu BioPharma, Inc. , a pharmaceutical company focused on advancing innovative medicines for complex central nervous system
- 10mo agoAYTUAytu BioPharma to Host Investor Day on January 20, 2026 in New York CityACCESS NewswireDENVER, CO / ACCESS Newswire / December 18, 2025 / Aytu BioPharma, Inc. , a pharmaceutical company focused on advancing innovative medicines for complex central nervous system
- 11mo agoAYTUAytu BioPharma Announces Commercial Availability of EXXUA(TM) (gepirone) Extended-Release Tablets, the First and Only 5HT1a Agonist Indicated for the Treatment of Major Depressive Disorder in AdultsACCESS NewswireEXXUA is now available through Aytu RxConnect® pharmacies to ensure optimal access and availabilityEXXUA has demonstrated significant improvement in depression symptoms in clinical trials involving more than 5,000
- 11mo agoAYTUAytu BioPharma to Participate in Noble Capital Markets 21st Annual Emerging Growth Equity ConferenceACCESS NewswireDENVER, CO / ACCESS Newswire / November 24, 2025 / Aytu BioPharma, Inc. , a pharmaceutical company focused on advancing innovative medicines for complex central
- 12mo agoAYTUAytu BioPharma Reports Fiscal 2026 First Quarter Operational and Financial ResultsACCESS NewswireTotal net revenue of $13.9 millionNet income of $2.0 million, or $0.21 net income per share basicAdjusted EBITDA1 of $ million, which includes EXXUA launch investments$32.6 million cash balance at September 30,
- 1y agoAYTUAytu BioPharma to Report Fiscal 2026 First Quarter Operational and Financial Results on November 13, 2025ACCESS NewswireDENVER, CO / ACCESS Newswire / November 5, 2025 / Aytu BioPharma, Inc. , a pharmaceutical company focused on advancing innovative medicines for complex central
- 1y agoAYTUAytu BioPharma Announces Patent Term Extension for EXXUA(TM)ACCESS NewswireDENVER, CO / ACCESS Newswire / October 28, 2025 / Aytu BioPharma, Inc. , a pharmaceutical company focused on advancing innovative medicines for complex central
- 1y agoAYTUAytu BioPharma to Present at Upcoming October 2025 ConferencesACCESS NewswireDENVER, CO / ACCESS Newswire / October 10, 2025 / DENVER, CO / ACCESS Newswire / October 10, 2025 /Aytu BioPharma, Inc. , a pharmaceutical company focused on
- 1y agoAYTUAytu BioPharma to Present at Upcoming September 2025 ConferencesACCESS NewswireDENVER, CO / ACCESS Newswire / September 24, 2025 / Aytu BioPharma, Inc. , a pharmaceutical company focused on advancing innovative medicines for complex central
- 1y agoAYTUAytu BioPharma Reports Fiscal 2025 Full Year and Fourth Quarter Operational and Financial Results and Outlines Commercial Launch Plans for EXXUA(TM)ACCESS NewswireFull year fiscal 2025 net revenue of $66.4 millionFull year fiscal 2025 net loss of $13.6 millionFull year fiscal 2025 adjusted EBITDA1 of $9.2 million$31.0 million cash balance at June 30, 2025Exclusive agreement in
- 1y agoAYTUAytu BioPharma to Report Fiscal 2025 Full Year and Fourth Quarter Operational and Financial Results on September 23, 2025ACCESS NewswireDENVER, CO / ACCESS Newswire / September 16, 2025 / Aytu BioPharma, Inc. , a pharmaceutical company focused on advancing innovative medicines for complex central
- 1y agoAYTUAytu BioPharma Appoints Dr. Gerwin Westfield as Senior Vice President of Scientific Affairs to Support Commercialization of EXXUA(TM)ACCESS NewswireDENVER, CO / ACCESS Newswire / June 25, 2025 / Aytu BioPharma, Inc. , a pharmaceutical company focused on advancing innovative medicines for complex central
- 1y agoAYTUAytu BioPharma Expands and Extends Lending Agreement with Eclipse Following Agreement to Commercialize First-in-Class Antidepressant EXXUA(TM)ACCESS NewswireTerm loan maturity extended by 12 months to June 2029Principal balance on term loan expanded to $13.0 million from $11.1 million currentlyExpanded revolving line of credit facility by $1.5 millionExpanded facilities
- 1y agoAYTUAytu BioPharma Announces Closing of Upsized At the Market Public Offering of Common Stock with Full Exercise of Overallotment and Conference Call to Discuss First-in-Class Antidepressant EXXUA(TM) Opportunity and Commercialization PlanACCESS NewswireGross proceeds from offering total $16.6 million.Financing led by long-term, healthcare-focused institutional investors, including Aytu's largest shareholders Nantahala Capital Management and Stonepine Capital
- 1y agoAYTUAytu BioPharma Announces At the Market Pricing of $14.4 Million Upsized Public Offering of Common StockACCESS NewswireNantahala Capital Management, Stonepine Capital Management, Aytu Management, and New Institutional Shareholders Lead Financing. DENVER, CO / ACCESS Newswire / June 6, 2025 / Aytu BioPharma, Inc. (the "Company"
- 1y agoAYTUAytu BioPharma Announces Exclusive Agreement with Fabre-Kramer Pharmaceuticals to Commercialize First-in-Class Antidepressant EXXUA(TM) (gepirone) Extended-Release Tablets in the United StatesACCESS NewswireAytu enters the over $22 billion United States prescription major depressive disorder market with the first-in-class oral selective serotonin 5HT1a receptor agonist for adults with MDD.EXXUA has
- 1y agoAYTUAytu BioPharma Reports Fiscal 2025 Third Quarter Operational and Financial ResultsACCESS NewswireNet income of $4.0 million, or $0.65 and $0.21 net income per share basic and diluted, respectivelyAdjusted EBITDA1 of $3.9 millionTotal net revenue of $18.5 million up 32% year-over-yearCompany to host conference call
- 1y agoAYTUAytu BioPharma to Report Fiscal 2025 Third Quarter Operational and Financial Results on May 14, 2025ACCESS NewswireDENVER, CO / ACCESS Newswire / May 7, 2025 / Aytu BioPharma, Inc. , a pharmaceutical company focused on commercializing novel therapeutics, will report its
- 1y agoAYTUAytu BioPharma to Present at the Planet MicroCap Showcase: VEGAS 2025 on April 23, 2025ACCESS NewswireCompany to conduct 1x1 meetings on April 24, 2025 DENVER, CO / ACCESS Newswire / April 21, 2025 / Aytu BioPharma, Inc. , a pharmaceutical company focused on
- 1y agoAYTUAytu BioPharma Reports Fiscal 2025 Second Quarter Operational and Financial ResultsACCESS NewswireNet income of $0.8 millionAdjusted EBITDA1 of $1.3 millionPediatric Portfolio net revenue up 86% sequentiallyFirst quarterly sequential prescription increase for both ADHD and Pediatric portfolios since Q2 fiscal
- 1y agoAYTUAytu BioPharma to Report Fiscal 2025 Second Quarter Operational and Financial Results on February 12, 2025ACCESS NewswireDENVER, CO / ACCESS Newswire / February 5, 2025 / Aytu BioPharma, Inc. , a pharmaceutical company focused on commercializing novel therapeutics, will report its
- 1y agoAYTUAytu BioPharma to Participate in the Lytham Partners 2025 Investor Healthcare Summit on January 13, 2025ACCESS NewswireDENVER, CO / ACCESSWIRE / January 6, 2025 / Aytu BioPharma, Inc. , a pharmaceutical company focused on commercializing novel therapeutics, today announced that
- 1y agoAYTUAytu BioPharma Disclosure NotificationACCESS NewswireDENVER, CO / ACCESSWIRE / December 3, 2024 / SUMMARY NOTICE OF PENDENCY OF DERIVATIVE ACTION, AGREEMENT OF SETTLEMENT AND RELEASE WITH RESPECT TO CERTAIN PARTIES, AND SETTLEMENT HEARING IN THE COURT OF CHANCERY OF THE
- 1y agoAYTUAytu BioPharma Ranked as One of Fastest-Growing Companies in North America on the 2024 Deloitte Technology Fast 500(TM)ACCESS NewswireDENVER, CO / ACCESSWIRE / November 22, 2024 / Aytu BioPharma, Inc. , a pharmaceutical company focused on commercializing novel therapeutics, today announced it
- 1y agoAYTUAytu BioPharma, Inc. (AYTU) Q1 2025 Earnings Call TranscriptEarnings Call Transcripts
- 1y agoAYTUAytu BioPharma Reports Fiscal 2025 First Quarter Operational and Financial ResultsACCESS NewswireNet income of $1.5 millionAdjusted EBITDA1 of $1.9 millionADHD Portfolio net revenue up 1% to $15.3 millionPediatric Portfolio net revenue up 54% sequentially$20.1 million cash balance at September 30, 2024Organizational
- 2y agoAYTUAytu BioPharma to Report Fiscal 2025 First Quarter Operational and Financial Results on November 13, 2024ACCESS NewswireDENVER, CO / ACCESSWIRE / November 6, 2024 / Aytu BioPharma, Inc. , a pharmaceutical company focused on commercializing novel therapeutics, will report its
- 2y agoAYTUAytu BioPharma to Participate in the 2024 Maxim Healthcare Virtual SummitACCESS NewswireDENVER, CO / ACCESSWIRE / October 14, 2024 / Aytu BioPharma, Inc. , a pharmaceutical company focused on commercializing novel therapeutics, today announced Josh
- 2y agoAYTUAytu BioPharma Announces Exclusive Agreement with Lupin Pharma Canada Ltd to Commercialize Adzenys XR-ODT(R) and Cotempla XR-ODT(R) in CanadaACCESS NewswireOnce approved by Health Canada, Adzenys and Cotempla will be the only orally disintegrating, extended-release tablets for the treatment of ADHD commercialized in Canada DENVER, CO / ACCESSWIRE / October 1, 2024 / Aytu
- 2y agoAYTUAytu BioPharma, Inc. (AYTU) Q4 2024 Earnings Call TranscriptEarnings Call Transcripts
- 2y agoAYTUAytu BioPharma Reports Fiscal 2024 Full Year and Fourth Quarter Operational and Financial ResultsACCESS NewswireFull year fiscal 2024 consolidated net revenue of $81.0 million; Rx Segment net revenue of $65.2 millionFull year fiscal 2024 ADHD Portfolio net revenue up 23% compared to fiscal 2023Full year fiscal 2024 adjusted
- 2y agoAYTUAytu BioPharma to Report Fiscal 2024 Full Year and Fourth Quarter Operational and Financial Results on September 26, 2024ACCESS NewswireDENVER, CO / ACCESSWIRE / September 19, 2024 / Aytu BioPharma, Inc. , a pharmaceutical company focused on commercializing novel therapeutics, will report its
- 2y agoAYTUAytu BioPharma to Participate in the Sidoti Micro-Cap Virtual Conference on August 14-15, 2024ACCESS NewswireDENVER, CO / ACCESSWIRE / August 8, 2024 / Aytu BioPharma, Inc. , a pharmaceutical company focused on commercializing novel therapeutics, today announced that
- 2y agoAYTUAytu BioPharma Announces Sale of Consumer Health Business Following Wind Down of Consumer Health OperationsACCESS NewswireConsumer Health Wind Down and Sale Maximizes Shareholder Value as Company Focuses on Rx SegmentEliminates Materially All Remaining Expenses Associated with the Consumer Health BusinessProvides for Receipt of Future
- 2y agoAYTUAytu BioPharma Announces Paydown and Refinancing of Term Loan on More Favorable TermsACCESS NewswireCompany receives proceeds of $3.5 million through exercise of warrants, a portion of which was used to pay down debtInterest rate on new $13.0 million term loan reduced by approximately 350 basis points today,
- 2y agoAYTUAytu BioPharma to Participate in the Lytham Partners Spring 2024 Investor Conference on May 30, 2024ACCESS NewswireDENVER, CO / ACCESSWIRE / May 23, 2024 / Aytu BioPharma, Inc. , a pharmaceutical company focused on commercializing novel therapeutics, today announced that Josh Disbrow,